Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells

被引:13
作者
Bikas, Athanasios [1 ,2 ]
Jensen, Kirk [3 ]
Patel, Aneeta [3 ]
Costello, John [3 ]
Kaltsas, Gregory [1 ]
Hoperia, Victoria [4 ]
Wartofsky, Leonard [5 ]
Burman, Kenneth [5 ]
Vasko, Vasyl [3 ]
机构
[1] Univ Athens, Laiko Hosp, Dept Pathophysiol, Athens 11527, Greece
[2] MedStar Georgetown Univ Hosp, Dept Internal Med, 3800 Reservoir Rd, Washington, DC 20007 USA
[3] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA
[4] Natl Univ Kyiv, Dept Fundamental Med, UA-01033 Kiev, Ukraine
[5] MedStar Washington Hosp Ctr, Div Endocrinol, Dept Internal Med, Washington, DC 20010 USA
关键词
mitotane; thyroid; cancer; thyroid cancer; mitochondria; apoptosis; ADRENAL-CORTICAL CARCINOMA; ADRENOCORTICAL CARCINOMA; GENE-EXPRESSION; GUIDELINES; MANAGEMENT; DIAGNOSIS; THERAPY;
D O I
10.3892/ijo.2019.4802
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mitotane is used for the treatment of adrenocortical cancer and elicits its anticancer effects via inhibition of mitochondrial respiration. Targeting mitochondria-dependent metabolism has emerged as a promising strategy for thyroid cancer (TC) treatment. We hypothesized that mitotane targets mitochondria and induces apoptosis in TC cells. Cell lines representative of the major histological variants of TC were chosen: Follicular (FTC-133), poorly differentiated (BCPAP), anaplastic (SW1736 and C643) and medullary (TT) TC cells, and were treated with mitotane (0-100 mu M). Mitochondrial membrane potential, cell viability and apoptosis were examined by JC-1 staining and by western blot analysis using an antibody against caspase-3. The expression of mitochondrial molecules and DNA damage markers and the activation of endoplasmic reticulum (ER) stress were determined by western blotting. The expression of mitochondrial ATP synthase subunit beta (ATP5B) was examined by immunostaining in 100 human TC tissue samples. Treatment with mitotane (50 mu M for 24 h) decreased the viability of FTC-133, BCPAP, SW1736, C643 and TT cells by 12, 59, 54, 31 and 66%, respectively. Morphological evidence of ER stress and overexpression of ER markers was observed in TC cells following exposure to mitotane. The treatment led to increased expression of histone gamma H2AX, indicating DNA damage, and to caspase-3 cleavage. Consistent with the results of the cell viability assays, the overexpression of pro-apoptotic genes following treatment with mitotane was more prominent in TC cells harboring mutations in the serine/threonine-protein kinase B-raf gene and proto-oncogene tyrosine-protein kinase receptor Ret. Treatment with mitotane was associated with loss of mitochondrial membrane potential and decreased expression of ATP5B, particularly in the medullary TC (MTC)-derived TT cells. Immunohistochemical analysis of mitochondrial ATP5B in human TC specimens demonstrated its overexpression in cancer compared with normal thyroid tissue. The level of ATP5B expression was higher in MTC compared with the follicular, papillary or anaplastic types of TC. Mitotane elicited pleiotropic effects on TC cells, including induction of ER stress, inhibition of mitochondrial membrane potential and induction of apoptosis. The results of the present study suggest that mitotane could be considered as a novel agent for the treatment of aggressive types of TC.
引用
收藏
页码:7 / 20
页数:14
相关论文
共 48 条
[1]   Korea's Thyroid-Cancer "Epidemic" - Screening and Overdiagnosis [J].
Ahn, Hyeong Sik ;
Kim, Hyun Jung ;
Welch, H. Gilbert .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (19) :1765-1767
[2]   Adrenocortical Carcinoma [J].
Baudin, Eric .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2015, 44 (02) :411-+
[3]   Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center [J].
Baudry, Camille ;
Coste, Joel ;
Khalil, Roula Bou ;
Silvera, Stephane ;
Guignat, Laurence ;
Guibourdenche, Jean ;
Abbas, Halim ;
Legmann, Paul ;
Bertagna, Xavier ;
Bertherat, Jerome .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (04) :473-481
[4]   Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Berruti, A. ;
Baudin, E. ;
Gelderblom, H. ;
Haak, H. R. ;
Porpiglia, F. ;
Fassnacht, M. ;
Pentheroudakis, G. .
ANNALS OF ONCOLOGY, 2012, 23 :131-138
[5]   Targeted therapies in thyroid cancer: an extensive review of the literature [J].
Bikas, Athanasios ;
Vachhani, Shivangi ;
Jensen, Kirk ;
Vasko, Vasyl ;
Burman, Kenneth D. .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) :1299-1313
[6]   Increasing Incidence of Differentiated Thyroid Cancer in the United States, 1988-2005 [J].
Chen, Amy Y. ;
Jemal, Ahmedin ;
Ward, Elizabeth M. .
CANCER, 2009, 115 (16) :3801-3807
[7]   Physiological functions of mitochondrial fusion [J].
Chen, Hsiuchen ;
Chan, David C. .
MITOCHONDRIAL RESEARCH IN TRANSLATIONAL MEDICINE, 2010, 1201 :21-25
[8]   Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5α-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement [J].
Chortis, Vasileios ;
Taylor, Angela E. ;
Schneider, Petra ;
Tomlinson, Jeremy W. ;
Hughes, Beverly A. ;
O'Neil, Donna M. ;
Libe, Rossella ;
Allolio, Bruno ;
Bertagna, Xavier ;
Bertherat, Jerome ;
Beuschlein, Felix ;
Fassnacht, Martin ;
Karavitaki, Niki ;
Mannelli, Massimo ;
Mantero, Franco ;
Opocher, Giuseppe ;
Porfiri, Emilio ;
Quinkler, Marcus ;
Sherlock, Mark ;
Terzolo, Massimo ;
Nightingale, Peter ;
Shackleton, Cedric H. L. ;
Stewart, Paul M. ;
Hahner, Stefanie ;
Arlt, Wiebke .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (01) :161-171
[9]   Future directions in the diagnosis and medical treatment of adrenocortical carcinoma [J].
Creemers, S. G. ;
Hofland, L. J. ;
Korpershoek, E. ;
Franssen, G. J. H. ;
van Kemenade, F. J. ;
de Herder, W. W. ;
Feelders, R. A. .
ENDOCRINE-RELATED CANCER, 2016, 23 (01) :R43-R69
[10]  
FANG VS, 1979, CANCER RES, V39, P139